It may be good science, but is it a good deal?

Explore our services
Why In-House Experience Matters
X
Clinical Trial Agreements
Commercial Agreements
Industry Collaborations
Private Financing
Strategic Transactions
University Collaborations
It may be good science, but is it a good deal?It may be good science, but is it a good deal?

When we look at a term sheet, we see a single piece of an overall business strategy.

Our goal is to design a transaction, not just to monetize IP, but also to drive the growth of your entire business. We can help you in the following ways:

Start-up

Start-up

License core technologies and obtain venture financing

Learn More
Clinical Study

clinical study

Launch and complete a complex clinical trial

Learn More
Partner

partner

Structure a research or product development collaboration

Learn More
Exit

exit

Close a strategic transaction for growth or exit

Learn More
Start-up

Start-up

License core technologies and obtain venture financing

Learn More
Clinical Study

clinical study

Launch and complete a complex clinical trial

Learn More
Partner

partner

Structure a research or product development collaboration

Learn More
Exit

exit

Close a strategic transaction for growth or exit

Learn More

Our lawyers started out on the industry side.

We came from pharma, life sciences and emerging technologies.
meet our professionalsWhy In-House Experience Matters
Our lawyers started out on the industry side.Our lawyers started out on the industry side.

We have deep experience.

We have worked with over 1000 companies, investors and research institutions in the life sciences and high-tech fields.
SEE OUR CLIENTS
ReveraGen BioPharma Inc.-Santhera Pharmaceuticals (Switzerland) Ltd— Idorsia Pharmaceuticals Ltd logos
ReveraGen BioPharma Inc.-Santhera Pharmaceuticals (Switzerland) Ltd— Idorsia Pharmaceuticals Ltd
Assignment, Amendment and Early Option Exercise Agreements

Assignment by Idorsia to Santhera of Idorsia’s option to license ReveraGen’s treatment for DMD in Phase III, and simultaneous amendment of the option agreement to provide for early exercise of Santhera’s option under revised terms

Press Release
Ipsen and University of Montreal Logos
Ipsen Bioscience Inc. - Université de Montréal
Research and Option Agreement to Acquire Exclusive License

Faber assisted Ipsen with a Research and Option Agreement under which Université de Montréal would conduct a lead optimization program on a high-value oncology program. Upon exercise of the option at the end of the research term, Ipsen would acquire an exclusive license for the worldwide rights to the program.

Press Release
Dermbiont Logo
DermBiont, Inc.
Series A Financing

$8 million Series A financing led by Viking Global Investors, Toba Capital and Zola Global Investors

Press Release
Blue Oak Logo
Blue Oak Pharmaceuticals, Inc.
Equity Securities

Equity Securities financing led by Viva Incubator Investment Management Limited and ShangPharma Investment Group

Website
Ipsen Bioscience Inc.— Blueprint Medicines Corp.
Exclusive License Agreement

Exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP) (including up to $535 million in potential development, regulatory and sales-based milestones and other payments, plus tiered percentage royalties)

Press Release
Intervenn Logo
InterVenn BioSciences
Series A Financing

Intervenn Bio raises a $9.4 million Series A financing led by biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV

Press Release
Lundbeckfond Logo
Lundbeckfond Ventures—New Enterprise Associates 14, LP
Royalty Sale

Lundbeckfond’s sale to New Enterprise Associates 14, LP of certain royalty rights receivable in connection with the merger of Vtesse Inc. with and into a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc.

Website
FogPharma Logo
FOG Pharmaceuticals, Inc.
Series B Financing

FogPharma raises $66,000,000 of Series B Financing, led by 6 Dimensions Capital L.P., with participation by GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group, Leerink Partners and all existing Series A investors

Press Release
Alnylam and Vir Logo
Alnylam Pharmaceuticals, Inc.—Vir Biotechnology, Inc.
Collaboration and License Agreement

Exclusive license with Vir Biotechnology to develop and commercialize RNAi therapeutics for chronic hepatitis B virus (HBV) infection and a research collaboration for other infectious diseases

Press Release
Sojournix Logo
Sojournix, Inc.
Series C Financing

Sojournix, Inc. raises Series C equity funding from RA Capital Management, Boxer Capital of the Tavistock Group, Frazier Healthcare Partners, Venrock Healthcare Capital Partners and Janus Henderson Investors

Press Release
Siamab Logo
Siamab Therapeutics, Inc.
Private Company Sale

Sale of Siamab’s tumor-associated carbohydrate antigen (TACA) discovery platform to a large commercial-stage biopharmaceutical company

Press Release
ImmunoGen Logo and Debiopharm International Logo
ImmunoGen, Inc. - Debiopharm International SA
Sale of Development Program

Sale of phase II antibody-drug conjugate assets from ImmunoGen for up to $55 million

Press Release
Lysosomal Therapeutics, Inc. Logo and Allergan plc Logo
Lysosomal Therapeutics, Inc.— Allergan plc
Exclusive Option to Aquire Company

Sale to Allergan of exclusive option to acquire LTI following completion of phase IB Clinical Trial

Press Release
Kite Pharma, Inc. Logo and Cell Design Labs Logo
Kite Pharma, Inc.—Cell Design Labs
Strategic Research Collaboration Agreement

Strategic Research Collaboration for CAR T-cell Immunotherapeutics

Press Release
Partners in Health Logo
Partners in Health
Clinical Trial

CRO and Site Agreements for Phase 4 Clinical Study of Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World

See Study
ReveraGen BioPharma Inc.-Santhera Pharmaceuticals (Switzerland) Ltd— Idorsia Pharmaceuticals Ltd logos
ReveraGen BioPharma Inc.-Santhera Pharmaceuticals (Switzerland) Ltd— Idorsia Pharmaceuticals Ltd
Assignment, Amendment and Early Option Exercise Agreements

Assignment by Idorsia to Santhera of Idorsia’s option to license ReveraGen’s treatment for DMD in Phase III, and simultaneous amendment of the option agreement to provide for early exercise of Santhera’s option under revised terms

Press Release
Ipsen and University of Montreal Logos
Ipsen Bioscience Inc. - Université de Montréal
Research and Option Agreement to Acquire Exclusive License

Faber assisted Ipsen with a Research and Option Agreement under which Université de Montréal would conduct a lead optimization program on a high-value oncology program. Upon exercise of the option at the end of the research term, Ipsen would acquire an exclusive license for the worldwide rights to the program.

Press Release
Dermbiont Logo
DermBiont, Inc.
Series A Financing

$8 million Series A financing led by Viking Global Investors, Toba Capital and Zola Global Investors

Press Release
Blue Oak Logo
Blue Oak Pharmaceuticals, Inc.
Equity Securities

Equity Securities financing led by Viva Incubator Investment Management Limited and ShangPharma Investment Group

Website
Ipsen Bioscience Inc.— Blueprint Medicines Corp.
Exclusive License Agreement

Exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP) (including up to $535 million in potential development, regulatory and sales-based milestones and other payments, plus tiered percentage royalties)

Press Release
Intervenn Logo
InterVenn BioSciences
Series A Financing

Intervenn Bio raises a $9.4 million Series A financing led by biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV

Press Release
© Faber Daeufer & Itrato PC. All Rights Reserved.
781 795 4700 main
|
Disclaimer
|
Attorney Advertising